Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Plan B lifts women's health for Teva: Second-quarter sales of the emergency contraceptive help drive a 3.9 percent increase in Teva Pharmaceuticals' women's health business to $80 million. Teva is in the midst of de-stocking Plan B inventory as Plan B One-Step -- a single-pill version of the two-pill original product -- becomes available in August, the Jerusalem-based firm said July 28 (1"The Tan Sheet" July 20, 2009). During a same-day earnings call, President and CEO Shlomo Yanai said the women's health business "has outstanding prospects for growth" and Teva intends to expand its oral contraceptive offerings
Advertisement

Related Content

Sales & Earnings In Brief
Sales & Earnings In Brief
With Exclusivity For Single-Dose Plan B, Teva Stays One Step Up On Generics
With Exclusivity For Single-Dose Plan B, Teva Stays One Step Up On Generics

Topics

Advertisement
UsernamePublicRestriction

Register

PS103191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel